Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of APG-1252 (Pelcitoclax) in SCLC and Solid Tumors
NCT03080311Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- Feb 2017
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelcitoclax in small cell lung cancer (SCLC) and solid tumor (2 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose. Started Feb 2017; status: completed.
02
Drugs
pelcitoclax
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT03080311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03080311.